The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

However, instead of directly editing a faulty gene, Casgevy instead takes advantage of a process that happens when babies are in the womb, where they make red blood cells with foetal haemoglobin ...

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.

The launch of Casgevy represents a pivotal moment for CRISPR Therapeutics. While initial uptake has been described as slow due to the lengthy treatment process, analysts note that the increase in ...

One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service.Most Read from BloombergHow the 2025 ...